Key Highlights
- Shares of Veracyte, Inc. (NASDAQ:VCYT) were quoted at USD 39.50, down 24.79%, in premarket trading on November 5, 2026, per the premarket quote.
- Third-quarter Revenue rose 15% to USD 151.8 million, with GAAP Net Income of USD 31.5 million and adjusted EBITDA of USD 41.2 million.
- 2026 testing revenue guidance was cut to USD 571 million to USD 573 million from USD 576 million to USD 582 million.
- The board authorized a share repurchase of up to USD 100 million over 12 months, and cash stood at USD 370.5 million.
Third-Quarter Results and a Lower Testing Range
Veracyte reported third-quarter 2026 results on November 4, 2026. Total revenue was USD 151.8 million, up 15% from USD 131.9 million. Testing revenue was USD 146.4 million, also up 15%, led by Decipher Prostate at USD 92.3 million, up 12%, and Afirma at USD 51.5 million, up 19%. Product revenue rose 40% to USD 4.6 million on Prosigna IVD adoption. The catalyst for the selloff appears to be the guidance: 2026 testing revenue is now expected at USD 571 million to USD 573 million, down from USD 576 million to USD 582 million. Total revenue guidance moved to USD 590 million to USD 593 million from USD 590 million to USD 596 million.
Profitability, Volumes and Management Tone
Profitability was strong. GAAP net income was USD 31.5 million, or 20.8% of revenue, and diluted GAAP Earnings Per Share were USD 0.38 against USD 0.24 a year earlier. Adjusted EBITDA was USD 41.2 million, a 27.2% Margin and up 4% from USD 39.7 million, while non-GAAP Diluted Earnings per Share of USD 0.51 were flat. Total test Volume rose 15% to 52,744, including about 29,900 Decipher Prostate tests and about 19,100 Afirma tests. Chief Executive Marc Stapley said: "We delivered solid third quarter results supported by strong profitability and cash generation." Adjusted EBITDA margin guidance of more than 26% was left unchanged. The pattern is a classic one: a diagnostics company can beat on volume and profit, but a lower forward revenue range resets the growth expectations built into the share price.
Cash, Risks and What to Watch
Cash, cash equivalents and short-term investments were USD 370.5 million at September 30, 2026. Operating Cash Flow was USD 40.3 million for the quarter and USD 121.3 million for nine months. The board also authorized a repurchase of up to USD 100 million of common stock, expiring in 12 months, which gives the company a way to retire shares if it chooses to use the program. Risks include slower testing revenue growth in the fourth quarter, reimbursement and payer dynamics for genomic tests, and concentration in two main products. Watch fourth-quarter volumes for Decipher Prostate and Afirma, how much of the buyback is used, and whether the lowered testing range proves conservative. A premarket quote is not a closing price and can move once regular trading begins.
Where Things Stand
The drop at Veracyte, Inc. (NASDAQ:VCYT) is best explained by the lowered 2026 testing revenue range, since the quarter itself showed 15% revenue growth, higher GAAP profit and strong cash flow. The balance of evidence favors a growth reset rather than a deterioration in earnings quality. The next catalyst is the fourth-quarter report, and the pace of any buyback.






Please wait processing your request...